innovate. collaborate. commercialise. - indian pharma… india 2016 brochure.pdf · innovate....

9
Innovate. Collaborate. Commercialise. www.terrapinn.com/biopharmaindia 15-16 November 2016 Hyatt Regency Mumbai, India 100+ local pharma & biotech companies 50+ Speakers 350 Attendees 1 event 2 Conference streams till 1 st July. Book your tickets today!

Upload: tranliem

Post on 19-Jul-2018

225 views

Category:

Documents


0 download

TRANSCRIPT

Innovate. Collaborate.

Commercialise.

www.terrapinn.com/biopharmaindia

15-16 November 2016 Hyatt RegencyMumbai, India

100+ local pharma & biotech

companies

50+ Speakers

350 Attendees

1 event2

Conference streams

till 1st July. Book your

tickets today!

Managing Director, Indian Immunologicals

GREAT EXPOSURE TO THE DEVELOPMENTS IN BIOPHARMA INDUSTRY - BOTH TECHNICAL AND COMMERCIAL ASPECTS.”

Join us as we navigate India’s biopharma future

India’s biopharma market has huge potential, there’s no doubt. But let’s take a moment to consider the generics market. Branded generics make up around 80% of India’s domestic pharmaceutical market, and India is a major generics supplier to the global pharma market. So how can we replicate that success and growth in India’s biopharma industry?

Welcome to BioPharma India 2016.

With a move towards a more transparent regulatory regime, strong efforts to encourage entrepreneurship and innovation, a widely available patient population and low manufacturing cost base, India is an attractive biopharma market, whether you’re a local company or an international pharma player. But we need to do more. If India is to become the number one pharma industry in the world, and wants to supply into the world’s most lucrative international markets, we need to continue to encourage new biotech start-ups to develop cutting-edge solutions and products, address quality assurance and control concerns, and create a coherent pricing and reimbursement strategy.

This November, together with leading biotech entrepreneurs, innovative start-ups and major pharma players from both within and outside India, BioPharma India will offer practical insights into how you can operate effectively in India’s biopharma market, whether from a manufacturing, branding or innovation perspective. We will also explore how you can leverage India’s strength to boost your presence in the global biopharma market.

BioPharma India isn’t a trade show. We bring senior executives together to explore the most exciting opportunities India’s biopharma industry has to offer. With case studies, innovation showcases and interactive panel discussions, you can hear from the movers and shakers and then meet them.

If you are part of India’s biopharma ecosystem, or want to be, you should join us.

100+ local pharma & biotech

companies

50+ Speakers

350 Attendees

1 event

2 Conference

streams

Contact Pinky Fadullon at (65) 6322 23738 or email [email protected] to get involved

Our story

WHO ATTENDS?

WHERE FROM?

COMPANIES WHICH ATTEND:

JOB TITLES

Who attends?

Research & Development

Medical AffairsProcess Development & Optimization

Drug or Vaccine Delivery

Government Affairs & Market Access

Chromatography

82%

India

9% Rest of Asia

Vice Presidents & Directors

22%

Others 16%

Managers & Heads 41%

Researchers, Engineers, Scientists

8% CXOs, Managing Directors, Presidents

10%

Local biotechstart-ups

Regulatory Compliance

Upstream / Cell culture

Drug Discovery

Business Units (Biosimilar, Vaccine, Oncology, Cardiology, etc)

Manufacturing Science and Technology (MSAT)

BioprocessPricing & Reimbursement

Facility Design

Research institutesQuality Assurance and Control

Manufacturing Technology

1% ROW

8% US & UK

The conferenceWe’ve restructured the event for 2016, to focus on the key challenges facing India’s biopharma industry.

Our brand new Therapeutic Innovation track (Day 1) will cover the latest breakthrough discoveries in the sector, including our Biotech Innovation Showcase, where groundbreaking Indian biotechs will offer 10-minute insights into their products, pipelines & pathway to commercialization.

Our Market Access track (Day 2) will offer practical insights into the realities of operating in India’s biopharma market, including pricing & reimbursement strategies, branding & communications, and also address the challenges of Indian biopharma businesses supplying the global market.

Our two-day Manufacturing track (Day 1 & 2) will focus on the key challenges facing India’s biopharma manufacturers and showcase the latest technologies shaking up the sector.

CONFERENCE DAY 1 – 15th November 2016

Therapeutic Innovation

Infectious Diseases & Cancer Vaccines

Biotech Innovation Showcase

Roundtable Discussion SessionChoose from our 8 roundtable discussions. Simply pick a table and join the debate.

Networking Lunch

Networking Refreshment Break

Opening Keynote Plenary: Encouraging innovation & entrepreneurship

Networking Refreshment Break

Networking Refreshment Break

Plenary: Innovative Partnering Models in India

Beers & Biotechs Networking Reception

Manufacturing

Process Development

Upstream

CONFERENCE DAY 2 – 16th November 2016

Market Access

Access & Reimbursement

Branding & Communications

Going Global

Networking Lunch

Networking Refreshment Break

Close of BioPharma India 2016

Keynote Plenary: Industry outlook

Manufacturing

Upscaling

Quality Assurance

Quality Control

Speak at the conference. Contact Pinky Fadullon at (65) 6322 23738 or email [email protected] to get involved

Abbott Healthcare Pvt. Ltd. Astrazeneca Pharma India Ltd Aura Biotechnologies Pvt Ltd Bayer Healthcare Bharat Serums And

Vaccines Ltd Biocon Research Limited Biological E Ltd Biotech Research Society India Boehringer Ingelheim Pharma G.M.B.H.

and Company K.G. Bristol-Myers Squibb Cadila Pharmaceuticals Ltd Central Drugs Standard Control Organization (West Zone)

Centre for Cellular and Molecular Platforms Cipla Ltd Clonz Biotech Pvt Ltd CPL Biologicals CSIR NIIST Trivandrum DGHS,

Dhaka, Bangladesh Dr. Reddys Laboratories Limited Eisai Pharmaceuticals India Pte Ltd Eli Lilly And Company India Ltd Enzene

Biosciences Ltd. Epirus Biopharmaceuticals, Inc. Finesse Solutions Glenmark Pharmaceuticals Ltd GSK India Haffkine Bio-Pharma

Corp Ltd Hetero Drugs Ltd Hospira Indian Immunologicals Limited Intas Pharmaceuticals Ltd J&J Innovation Centre Lupin Ltd Msd

Wellcome Trust Hilleman Labs Novalead Pharma Panacea Biotec Pfizer India Regrow Reliance Life Sciences Seagull BioSolutions

Pvt. Ltd. Shantha Biotechnics Stelis Biopharma Stempeutics Research Strand Life Sciences Ltd Tran-Scell Biologics Pvt. Ltd

Vatera Holdings Llc Vyome Biosciences

Director, Advent Worldwide

EXCELLENT OPPORTUNITY TO MEET TOP DECISION MAKERS, WHO ARE NORMALLY IN-ACCESSIBLE.”

“ Advisory Board

Dr Ajith V. Kamath

Senior Director and Head, External R&D Innovation, IndiaWorldwide Research & DevelopmentPfizer Inc.

Prof Ashok Pandey

Founder President, Biotech Research Society India, Former Chief Scientist and Head of Biotechnology Division, CSIR National Institute for Interdisciplinary Science and Technology

Dr G S Reddy

Chief General Manager, ManufacturingIndian ImmunologicalsLimited

Dr Kaushik Desai

Honorary General SecretaryIndian Pharmaceutical Association

Dr Sandhya Kumaraswamy

Associate Director, Quality AssuranceDr Reddy’s Laboratories

Dr Manjunath Ramarao

Group Director and Head, Disease Sciences and TechnologyBristol-Myers Squibb

Mr Swapnil BallalSenior DirectorDr Reddy’s Laboratories

Subhra Ranjan Chaktrabarti Associate Vice President Shantha Biotechnics (a Sanofi Company)

If you have an interesting case study to share, please contactEmily Chong at (65) 6322 2339 or email [email protected]

Speakers

Pazhanimuthu Annamalai Managing Director, AuraBiotech

Sudeep Singh GadokSenior Vice President, Enterprise Development, MSD Wellcome Trust Hilleman Labs

Atin Tomar President, CPL Biologicals

Ravishankar KasturiAsst. Vice President and Head of Manufacturing & Process Development, Reliance Life Sciences

Harish ShandilyaHead Global Product Development and Regulatory Affairs, Enzene Biosciences, part of Alkem Laboratories

Subhadra DravidaCo-Founder and CEO, Transcell

Stefan HartDirector, New Ventures, Johnson & Johnson

Rajinder Kumar SuriSenior Advisor and Former Chief Executive Biologicals, Panacea Biotech

Vikram Paradkar, Senior Vice President, Technical Operations, Biological E

Satyen SanghaviChief Scientific Officer, Regrow

Madhavan NampoothiriPrincipal Scientist and Head, Biotechnology Division, CSIR-NIIST

B N ManoharCEO & MD, Stempeutics

Neelam MukherjeeRegional Manager, Clinical Development Quality Assurance, APAC, Japan and EM, R&D, GSK

Venkateswarlu NelabhotlaCo-Founder & CEO, Vyome Biosciences

Davinder GillCEO, MSD Wellcome Trust Hilleman Labs

Ankur Bhatnagar, Associate Director, Biocon

Supreet DeshpandeCEO, NovaLead Pharma

Nirav DesaiVice President, CPL Biologicals

Dhaval TrivediAssistance Vice President, Regulatory Affairs, Stelis Biopharma (Strides Shasun Entreprise)

Barbara Paldus CEO, Finesse

Sundar KodiyalamManaging Director and Co-Founder, Vatera Healthcare Partners

Alok SharmaPrincipal Scientist and Head, Analytical Development Lab, Biotech Division, Lupin Limited

Chandru Chawla, Head of Corporate Strategy and New Ventures, Cipla

Arnab KapatDirector, Reliance Institute of Life Sciences and Vice President, Reliance Life Sciences

Natasha ShankerAssociate Director, Quality Control, Dr Reddy’s Laboratories

Vijay ChandruExecutive Chairman, Strand Life Sciences

SD SinhaVice President, Global Pharmacovigilance Clinical Development and Medical Affairs, Hetero Drugs Ltd

Rajendra JaniSenior Vice President, Clinical R&D, Zydus Cadila

Randy HiceManager, Global Strategy Abbott Information

Manoj KumarDirector, R&D, MSD Wellcome Trust Hilleman Labs

If you have an interesting case study to share, please contact

Emily Chong at (65) 6322 2339 or email [email protected]

AGENDA DAY ONE AGENDA DAY ONETUESDAY, 15 NOVEMBER 2016 TUESDAY, 15 NOVEMBER 20161/2 2/2OPENING KEYNOTE PLENARY: ENCOURAGING INNOVATION AND ENTREPRENEURSHIP

09:30

GUEST OF HONOUR KEYNOTE OPENING ADDRESS

Fostering biotechnology innovation and entrepreneurship in India - Where we are now & what’s next?India is the third largest biotechnology economy in the APAC region and the number 1 producer of Hepatitis B vaccines recombinant. As biotechnology brings solutions to the needs and problems of human society in the coming years, government support is paramount to the success of this industry. Join this session to find out how India’s government is working to encourage biotechnology and entrepreneurship in India.

Addressing pricing, reimbursement and compulsory licensing issues in IndiaPricing remains a contentious issues in India. While it is understandable that various government agencies try to reduce drug prices to ensure affordability in India, the lack of reimbursement and potential compulsory licensing of products pose serious operational challenges to pharmaceutical companies. The big question here, is how can we find the middle point between pharma and government, to ensure success for all concerned?

Organiser’s opening remarks

Chair’s opening remarks

10:00

15:20

16:00

Bridging the gap between research and commercialisation in the development of novel bacterial vaccines• Understanding the major hurdles to bringing novel vaccines

to commercialisation phase• Strategies for encouraging production of more

‘commercialisable’ and patentable innovations• Training and developing younger talents to instil use-inspired

researchManoj Kumar, Director, R&D, MSD Wellcome Trust Hilleman Labs

This exciting new addition to BioPharma India 2016 will see 8 of India’s most exciting and innovative biotechs offering 10-minute insights into their products, pipelines and their pathway to commercialization. Join us and hear from the innovators at the forefront of India’s biotech sector.

Chairman:Sundar Kodiyalam, Managing Director and Co-Founder, Vatera Healthcare Partners

Biotech companies:• Satyen Sanghavi, Chief Scientific Officer,

Regrow• B N Manohar, CEO & MD, Stempeutics• Subhadra Dravida, Co-Founder and CEO,

Transcell• Supreet Deshpande, CEO, NovaLead

Pharma• Pazhanimuthu Annamalai, Managing

Director, AuraBiotech• Vijay Chandru, Executive Chairman,

Strand Life Sciences• Vishwas D Joshi, Director, Seagull

Biosolutions• Venkateswarlu Nelabhotla, Co-Founder

& CEO, Vyome Biosciences

The role of bio-manufacturing plant automation in productivity enhancement, quality improvement and regulatory compliance • Understanding automation in the bio-manufacturing context• Exploring productivity enhancement through the seamless

automation of unit operations• Meeting international regulatory standards through

automated solutions Arnab Kapat, Director, Reliance Institute of Life Sciences and Vice President, Reliance Life Sciences

Managing multi-batch manufacturing: An upstream perspective• Understanding the requirements for managing multi-batch upstream processes• Building scalable, flexible control platform with multi-batch production tools • Using centralised plant management to avoid cross contaminationRavishankar Kasturi, Assistant Vice President and Head of Manufacturing & Process Development, Reliance Life Sciences

Overcoming quality issues in clinical development and research in India• Meeting the challenges of fulfilling Indian clinical trial

requirements• Exploring solutions to improve India’s clinical trials results

and quality• Improving clinical data with risk-based monitoring: A

case studyNeelam Mukherjee, Regional Manager, Clinical Development Quality Assurance, APAC, Japan and EM, R&D, GSK

Innovating vaccine manufacturing in India: Where are we now?• Addressing the challenges imposed by regulatory restrictions

on vaccine manufacturers• Overcoming the complexity of improving vaccine manufacturing

processes to increase efficiency and reduce cost• Understanding the role of vaccine manufacturers in

innovating processes to remain competitive in quality and product pricing

Subhra Ranjan Chaktrabarti, Associate Vice President, Shantha Biotechnics (a Sanofi Company)

Understanding the role of venture capital in duplicating India’s generics success to NCE and biologics development• Exposing Indian scientists and entrepreneurs to alternative

funding and sources of capital for building a biotech in India• Building a successful biotech/specialty pharma company: A

case study• What does it take to secure venture capital funding: Elements

of a successful business planSundar Kodiyalam, Managing Director and Co-Founder, Vatera Healthcare Partners

Understanding India’s latest biosimilar guidelines: How to make sure you’re compliant CDSCO share what you need to take note of when:• Documenting your upstream process • Producing upstream kinetics data • Reproducing fermentation data before upscaling from pilot scale

Bringing drugs targeting in tuberculosis fromthe laboratory to the commercial phase • Discovering the latest tuberculosis research in India • Working with industry partners to make the next scientific breakthrough• Understanding the best partnership and discovery model for scientific communities in IndiaMadhavan Nampoothiri, Principal Scientist and Head, Biotechnology Division, CSIR-NIIST

Building a seamless, smart production facility in India• Discovering strategies to overcome challenges in scaling up

production values from lab to manufacturing• Exploring smart technologies available for effective

manufacturing process design • Balancing the costs and benefits in implementing a smart

factory in India Barbara Paldus, CEO, Finesse

Chair’s opening remarks Chair’s opening remarksBarbara Paldus, CEO, Finesse

Networking Refreshment Break

Networking Refreshment Break

MANUFACTURING

UPSTREAM

PROCESS DEVELOPMENTTHERAPEUTIC INNOVATION

BIOTECH INNOVATION SHOWCASE11

:05

14:0

0

11:0

5

14:0

0

11:4

5

11:4

5

12:0

5

12:0

5

11:2

5

11:2

5

Improving cell density, productivity and scalability in antibody production • Investigating the limitations of current antibody production methods• Discovering how upstream perfusion helps to improve cell

density and productivity• Understanding how perfusion systems help to build flexibility

in scaling production sizesAnkur Bhatnagar, Associate Director, Biocon

Developing a cell-based vaccine manufacturing process• Exploring the potential for mass production of cell-based

influenza vaccines• Strategies to generate mammalian cell lines for vaccine production• Balancing the cost and efficiency of cell vs egg based productionSenior representative, Merck

14:4

015

:00

14:2

0

11:0

0

11:0

0

08:50

08:55

09:00

ROUNDTABLE DISCUSSION SESSIONChoose from our 8 roundtable discussions. Simply pick a table and join the debate.

Table 3: Integrating continuous

processing with existing biophamanufacturing facilities

Table 5: Low cost, high quality

biomanufacturing

Table 7: Improving novel cell lines to

improve expression and quality

PLENARY: INNOVATIVE PARTNERING MODELS IN INDIA

Making affordable, accessible, and thermo-stable vaccines in India Due to insufficient cold chain infrastructure, providing essential vaccines to less accessible regions is a great challenge in India. To overcome this difficulty, researchers worked to create thermo-stable biological products to minimize the need of cold chain services in storage and transportation stages. Leading Hilleman Labs, a joint venture between MSD and WEllcome Trust, Dr Davinder Gill, its CEO Of Hilleman Labs shares their journey from development of thermo-stable, to finding the right manufacturing partner, and improving access to essential vaccines to prevention of diseases in India. Davinder Gill, CEO, MSD Wellcome Trust Hilleman Labs

Managing partnerships in joint-venture settings Joint venture is among the popular choices in for-profit company to improve visibility and reach in global pharmaceutical industry. Representing CPL Biologicals as its newly appointed president, Atin joins us in this conference to share his view on the key strategies for him and his team in managing the different aspects of this India-USA joint venture in India. Key discussions include managing stakeholder relationship, creating melting pot in the organisation, recruiting and retaining talents and moving forward from status quo.Atin Tomar, President, CPL Biologicals

16:50

17:10

BEERS & BIOTECHS NETWORKING SESSIONGrab a beer and join us for this exciting session where 8 exciting new biotechs will have the opportunity to showcase their elevator pitch.

Hear from some of India’s hottest new biotech prospects whilst enjoying a drink – don’t forget to bring your business cards!

17:30With so much great content, book you tickets now. Or bring your team! There are special group packages available. Call Pinky Fadullon at (65) 6322 23738 or email [email protected]

12:25 Networking Lunch

Supporting continuous upstream processing with advanced single use technology• Discovering how single use technology can help build next

generation continuous bioprocessing systems• Overcoming implementation challenges of single use

technology in the existing manufacturing facilities• Exploring the potential for building fully single use bio

manufacturing in IndiaSenior representative, Wipro-GE Healthcare

Table 1:Building local and international

partnershipsStefan Hart, Director, New Ventures,

Johnson & Johnson

Table 4: Improving healthcare access

in IndiaSudeep Singh Gadok, Senior Vice President, Enterprise Development, MSD Wellcome Trust Hilleman Labs

Table 2: Building an innovation

ecosystem in India - where we are now and what’s next?

Table 6: GMP in biomanufacturing

Table 8: Upscaling novel therapeutic

productsSenior representative, Merck

AGENDA DAY TWO AGENDA DAY TWOWEDNESDAY, 16 NOVEMBER 2016 WEDNESDAY, 16 NOVEMBER 20161/2 2/2KEYNOTE PLENARY: INDUSTRY OUTLOOK

09:30

FROM IMITATOR TO INNOVATOR: HOW INDIA CAN BECOME THE NEXT INTERNATIONAL R&D DESTINATION FROM AN API & GENERICS MANUFACTURING HUB With increasingly skilled and affordable labour, and a growing commitment to strengthening IPR and infrastructure within the country, India is now transforming itself from an API and generics manufacturer to an innovation-driven manufacturing hub. Find out how India can improve its infrastructure and create more transparent policies to encourage its growth into future pharmaceutical and medical devices hub. Rajinder Kumar Suri, Senior Advisor and Former Chief Executive Biologicals, Panacea Biotech

KEYNOTE PANEL DISCUSSION: BIOPHARMA INDIA INDUSTRY OUTLOOK 2020 Whilst India is set on the path to growth, we undoubtedly still face some challenges. To attract more foreign direct investment, we need to overcome fragmented policy and funding shortages, and further improve infrastructure and IPR protection. In this session, a panel of analysts and pharma leaders will address the following topics:• Where are we now in encouraging innovation in India?• Repositioning India as a new innovation hub by building a sustainable ecosystem• Advice to local biotechs: Strategies to build up a strong base in India without losing out to competition• Shooting for success: Strategies for replicating India’s success in generics to become the global leader in biologics production and research

Chair’s opening remarks

10:10

Balancing access, quality and cost: What are the best pricing strategies for antibodies and biosimilars in India?• Improving accessibility and affordability of prescription drugs by setting a price ceiling• Understanding how biosimilars pricing policies affect opportunities for domestic and international pharma players• Investigating methods to reduce operational costs to remain profitable while reducing product prices

PANEL DISCUSSION: Moving beyond traditional reimbursement pathway to make drugs more affordable in IndiaLess than 1% of India government’s GDP is invested yearly in healthcare research and reimbursement. In this panel discussion, regulators and pharma leaders investigate the topics below in an attempt to build a more sustainable healthcare ecosystem in India:

• How can the government better support local companies to build a stronger domestic pharmaceutical market?• What is the role of pharma in making drugs more affordable while remaining profitable?• Alternative models to provide affordable drugs without depending on traditional reimbursement models

Navigating India’s regulatory landscape to get your new drugs and biosimilars approved • Understanding the current challenges in getting new drugs

and clinical trials approved in India• Crafting corrective measurements to improve drugs and trials

approved in India• Getting your biosimilars approved in India- A case study

Building a hybrid system to create a scalable manufacturing facility• Balancing costs and benefits by creating a hybrid manufacturing facility in India• Achieving production scale flexibility by integrating traditional manufacturing techniques with semi-perfusion systems• Exploring how single use technology can help in scaling manufacturing production

Chair’s opening remarks Chair’s opening remarks

Networking Refreshment Break

MANUFACTURINGUPSCALING

MARKET ACCESSACCESS AND REIMBURSEMENT

10:5

5

10:5

5

11:3

5

11:3

511

:55

11:1

5

14:50

Bringing Indian biologics products to global markets – A case study of CPL Biologicals• From early stage development to the manufacturing phase-

how Indian biologics manufacturers can comply with regulatory guidelines and ensure high quality development and production

• Overcoming regulatory challenges in exporting Indian products to the global market

• Bridging the gap between India and international health product rules and requirements

Nirav Desai, Vice President, CPL Biologicals

Building a “patient-first” brand in India• Understanding what it means to be a truly “patient-first”

business• How can you demonstrate “patient-first” as a key element of

your brand, whether you are a local or international player?• How can different functions within your business work

together to consolidate this approach?

Developing an effective medical communications strategy for India’s biopharma market• What restrictions are there on marketing strategies for

biopharmaceuticals in India?• How can you reach your market? • The bridge between development and commercialisation: What

role does medical affairs play in your communications strategy? • Balancing commercial value whilst delivering credible

medical information

Establishing health economics and outcome research (HEOR) data to your expand international market share • Strategies for presenting clinical and economic evidence to makers, payers and providers in the international arena• Gaining market access and reimbursement with convincing HEOR data• Delivering essential courses to provide trained workforce to conduct HEOR studiesRajendra Jani, Senior Vice President, Clinical R&D, Zydus Cadila

Biosimilars comparability studies and method development in early phase production• Building target-specific, robust testing kits• Ensuring reproducibility of biologics kits• Optimising assays to ensure successful regulatory

submissionAlok Sharma, Principal Scientist and Head, Analytical Development Lab, Biotech Division, Lupin Limited

Selecting the right CMO to produce high quality biologics products• Analysing the most important factors to consider when

deciding on a CMO to serve your manufacturing objectives • Differentiating industry reputation and brand recognition from

marketing promotional strategies• Cost versus usage rate- are you making the right choice

when selecting your CMO?

Laboratory Information Management Systems (LIMS) as compliance management tool• How can modern LIMS keep a company compliant?• Increasing productivity & confidence by reducing transciption

and calculation errors• Tools to assure quick response to regulatory audits Randy Hice, Manager, Global Strategy, Abbott Informations

Establishing proper control strategies for a risk free commercial manufacturing• Identification of critical quality attributes • Drafting effective control strategies to ensure quality

biosimilars production• Working closely with regulators to minimise risk• Continuous process verificationHarish Shandilya, Head Global Product Development and Regulatory Affairs, Enzene Biosciences, part of Alkem Laboratories

Networking refreshment break

15:35 Closing Networking Refreshments

QUALITY CONTROLGOING GLOBAL

15:2

013

:50

14:1

014

:30

15:2

014

:10

14:3

013

:50

10:5

0

10:5

0

09:00

09:10

Overcoming downstream bottlenecks in the upscaling process• Investigating how efficient downstream process help to establish flexible manufacturing systems • Strategies for reducing your downstream footprint whilst speeding up the purification process • Selecting the best innovative tools to overcome downstream bioproduction bottlenecks

12:15 Networking Lunch

From Bedside to Market- Strategies for transitioning from an investigator to a prescriber • How is the role of medical affairs personnel evolving, and how

can you use it as a tool for building recognition in the market?• Identifying the key stakeholders you need to be interacting

with to build credibility

Quality risk management (QRM) in implementing new bioprocesses• Developing the best tools to implement QRM in bioprocessing• From batch to continuous processing, how can pharma

manufacturers manage the inherent risks?

QUALITY ASSURANCE BRANDING & COMMUNICATIONS

13:3

0

13:3

0

Showcase your technologies to the BioPharma India audience. Contact Pinky Fadullon at(65) 6322 2738 or email [email protected] for a discussion on how you can be involved.

PANEL DISCUSSION: Scalable, single use, and continuous systems for improving biomanufacturing productivity in India: What’s possible?• Understanding the current regulatory challenges in

implementing new biomanufacturing processes in Indian manufacturing plants

• Exploring strategies to improve productivity with robust and scalable technology transfer systems

• Investigating cost effective methods to implement single use manufacturing systems in India

• Understanding how continuous systems help to improve productivity and scalability of biologics production

• Developing critical attributes to effectively monitor scalable, single use and continuous manufacturing process

• Performing the right comparability assessments to ensure system robustness

Moderator: G S Reddy, Chief General Manager, Manufacturing, Indian Immunologicals LimitedPanellists: Vikram Paradkar, Senior Vice President, Technical Operations, Biological E

Successfully launching biosimilars in international markets• Providing essential efficacy data to speed up biosimilars

launch in international markets• Justifying pre- and post- launch marketing investment to

improve brand awareness• Building international confidence in Indian biosimilar products• How can we replicate India’s success as the number one

generics supplier to achieve the same status in the global biologics industry?

Chandru Chawla, Head of Corporate Strategy and New Ventures, Cipla

From development to validation: Analytical method LCM and its associated challenges• Overview of various method development approaches and

highlighting stability indicating assays • Method validation & performance tracking to cope with latest

configurations, reagents and alternatives• Exploring automation as a method for streamlining QC

processes and maintaining uniformity of analytical processes• Balancing benefits and limitations of automation in data analysis.Natasha Shanker, Associate Director, Quality Control, Dr Reddy’s Laboratories

15:4

0

15:4

0

Branding strategies for supplying drugs to international market• Overcoming international concerns around the quality of

Indian products• Building relationships with the right people to ensure

branding success• Overcoming the challenge of a lack of brand recognition in

foreign markets

Design principles for conducting GMP stability storage and biological stability testing• Crafting critical quality attributes and stability testing

strategies • Deriving control strategies to ensure identity, drug quality,

purity and potency • Developing stability protocols for GMP stability testing

16:0

0

16:0

0

13:3

0

13:3

0

• Providing value-added services to patients and other personnel to establish a market leadership positionpersonnel to establish a market leadership position

SD Sinha, Vice President, Global Pharmacovigilance Clinical Development and Medical Affairs, Hetero Drugs Ltd

• Batch vs Semi-batch vs continuous processing: Comparing risk management perspectivesDhaval Trivedi, Assistance Vice President, Regulatory Affairs, Stelis Biopharma (Strides Shasun Entreprise)

BioPharma India will serve as a marketplace bringing all elements of the eco system together. Regulators, local biotechs, global pharmas, IP consultants, manufacturing equipmentproviders, API and cell line providers and regulatory consultants will come together, allowing India’s biotechs to assess topics such as: drug development, manufacturing and quality.

This event is your prime opportunity to meet with regulators, local pharma representatives and biotech start-ups with local expertise as they look to adopt new technologies to accelerate their drug development.

Why sponsor?ways to engage clients8

If your area of expertise falls under these categories, then you should be exhibiting at BioPharma India 2016:

Manufacturing solutions

• Scale-up• BioreactorsPlatform technology• Purification/ Decontamination• Process Design/ Optimization• Contract Design & Manufacturing

Market Access• Pricing & reimbursement• Health economics• Health communications• Pharma marketing

Research & development solutions

• Vaccine delivery technology• Protein characterization• Biosimilar comparability

Quality Assurance/Control solutions

• GMP Audit• Temperature & humidity control• Cold chain supply• Track & trace

EXHIBITShowcase yourself to over 300 of India’s leading biopharma players by taking a stand on the exhibition floor.

THOUGHT LEADERSHIP PRESENTATIONSDeliver your message as a thought leader on a chosen topic to a room of senior decision makers from India’s local pharma.

PANEL DISCUSSIONSSit alongside the leaders in India’s biopharma industry to discuss key challenges of the market on one of our expert panel discussions.

CASE STUDY PRESENTATIONSShowcase your best customer case study to establish awareness and viability to a room full of prospects.

ROUNDTABLESHost a roundtable of up to 20 industry professionals around a key topic. The format is a really powerful forum to meet qualified, self-selected attendees to debate a problem they have, that you can solve.

WORKSHOPSHost an exclusive workshop on a topic chosen by you for up to 20 prequalified biopharma leaders.

BRANDINGThis event is already being marketed by us. The sooner you join the more exposure you will get, via our website and other digital channels, print media and online community.

LEAD GENERATIONThis is a digital inbound marketing program that uses social marketing and CRM to create awareness for your product or services. It allows you to generate leads that you can add to your sales pipeline.

Contact Pinky Fadullon at (65) 6322 23738 or email [email protected] to get involved

1 Finesse

Reserved

Reserved

Merck

Kaneka

BioPharmaSpec

Reserved

Abbott Informatics

ACRO Biosystems

Prometic

Malvern Aimil

GE Healthcare

Reserved

Reserved

Unchained

Reserved

PLUSS Advanced Technologies

9

A

2

10

B

3

11

C

4

12

D

5

13

E

6

14

F

7

15

8

16

STAGE STAGE

1 2

4

6

8

10

11 12

3

5

7

9

CONFERENCE ROOM 1

CONFERENCE ROOM 2

ENTRANCE/EXIT

TABLE TOP BOOTHS

POD-STANDS

RESERVED/SOLD

1516 1314

NETW

ORKI

NG L

UNCH

& D

RINK

S

TABLE TOP BOOTHS POD-STANDS RESERVED/SOLD

A B C D E F

Partner with us: The BioPharma India opportunity

Benefits Platinum Gold Silver Exhibitor

Plenary Keynote Presentation 1

Conference Track Chair 1

Conference Track Presentation 1 1

Hosted Roundtable Discussions 1 1 1

Staff Conference Passes 3 2 1 0

Client Conference Passes 5 4 3 0

Table-top Booth Yes Yes Yes Pod-stand

You’ve got goals? We can help you achieve them. We can work with you to achieve your targets in 2016 by positioning your brand in front of India’s biopharmaceutical industry. Join us as a sponsor to:

Meet, interact and network with senior level decision makers from India’s biopharma industry

Generate qualified and targeted leads for your sales team

Showcase your solutions to an audience keen to explore new technology

Extend your marketing footprint within India’s biopharma space

Sponsors & exhibitors

Gold Sponsors

Silver Sponsors

Contact Pinky Fadullon at (65) 6322 23738 or email [email protected] to get involved

For sponsorship or exhibition opportunities, contact Pinky Fadullon at (65) 6322 23738 or email [email protected] to get involved

Exhibitors